1 April 2026 in Biological Products. Prevention, Diagnosis, Treatment
INTRODUCTION. The spread of antibiotic-resistant mycobacteria necessitates new therapeutic approaches for tuberculosis, phage therapy being one of them. Liposomal mycobacteriophages are considered to be a way to enhance their efficacy; however, a comprehensive assessment of their stability is warranted for the further use of such preparations. AIM. This study aimed to evaluate the long-term stability (over six months) of a liposomal form of mycobacteriophage D29 under storage conditions at 4 °C based on a set of physicochemical and functional parameters to substantiate its further preclinical study. MATERIALS AND METHODS. The stability of liposomal form D29 was assessed over six months of storage at 4 °C. Sampling was performed at the following time points: 0; 1.5; 3; 4.5; and 6 months. The degree of phage encapsulation (%) was quantified by real-time polymerase chain reaction (qPCR). The surface charge (zeta potential) was measured by electrophoretic light scattering (Doppler electrophoretic mobility). Liposome morphology was analyzed using transmission electron microscopy. Functional activity was assessed by determining lytic activity via the Grazia titration method on M. smegmatis mc² 155 culture. RESULTS. High stability of the liposomal phage D29 form was demonstrated. Lytic activity remained at a level of ~10 9 PFU/mL throughout the storage period (six months, 4 °C). The degree of encapsulation decreased insignificantly (>88% of the initial value). The constant zeta potential value (from –6.1±0.3 to –8.2±0.5 mV) confirmed colloidal stability of the suspension without particle aggregation throughout the entire storage period. CONCLUSIONS. The liposomal mycobacteriophage D29 demonstrates high physicochemical and functional stability after long-term storage (six months, 4 °C), with preserved lytic activity and a high degree of encapsulation. The findings substantiate the prospects for further preclinical and subsequent clinical trial of this preparation designed to treat mycobacterial infections.